AU2016365829B2 - Treatment of cancer with dual targeting of CD47 and EGFR - Google Patents

Treatment of cancer with dual targeting of CD47 and EGFR Download PDF

Info

Publication number
AU2016365829B2
AU2016365829B2 AU2016365829A AU2016365829A AU2016365829B2 AU 2016365829 B2 AU2016365829 B2 AU 2016365829B2 AU 2016365829 A AU2016365829 A AU 2016365829A AU 2016365829 A AU2016365829 A AU 2016365829A AU 2016365829 B2 AU2016365829 B2 AU 2016365829B2
Authority
AU
Australia
Prior art keywords
antibody
egfr
cells
sirpa
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016365829A
Other languages
English (en)
Other versions
AU2016365829A1 (en
Inventor
Piero D. Dalerba
Doris Po Yi HO
Kelly Marie MCKENNA
Jens-Peter VOLKMER
Irving L. Weissman
Stephen WILLINGHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2016365829A1 publication Critical patent/AU2016365829A1/en
Application granted granted Critical
Publication of AU2016365829B2 publication Critical patent/AU2016365829B2/en
Priority to AU2020202712A priority Critical patent/AU2020202712B2/en
Priority to AU2023201938A priority patent/AU2023201938B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2016365829A 2015-12-11 2016-12-08 Treatment of cancer with dual targeting of CD47 and EGFR Active AU2016365829B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020202712A AU2020202712B2 (en) 2015-12-11 2020-04-23 Treatment of cancer with dual targeting of CD47 and EGFR
AU2023201938A AU2023201938B2 (en) 2015-12-11 2023-03-30 Treatment of cancer with dual targeting of CD47 and EGFR

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562266470P 2015-12-11 2015-12-11
US62/266,470 2015-12-11
US201662380177P 2016-08-26 2016-08-26
US62/380,177 2016-08-26
PCT/US2016/065641 WO2017100462A2 (en) 2015-12-11 2016-12-08 Treatment of cancer with dual targeting of cd47 and egfr

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202712A Division AU2020202712B2 (en) 2015-12-11 2020-04-23 Treatment of cancer with dual targeting of CD47 and EGFR

Publications (2)

Publication Number Publication Date
AU2016365829A1 AU2016365829A1 (en) 2018-06-07
AU2016365829B2 true AU2016365829B2 (en) 2020-02-06

Family

ID=59013321

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016365829A Active AU2016365829B2 (en) 2015-12-11 2016-12-08 Treatment of cancer with dual targeting of CD47 and EGFR
AU2020202712A Active AU2020202712B2 (en) 2015-12-11 2020-04-23 Treatment of cancer with dual targeting of CD47 and EGFR
AU2023201938A Active AU2023201938B2 (en) 2015-12-11 2023-03-30 Treatment of cancer with dual targeting of CD47 and EGFR

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020202712A Active AU2020202712B2 (en) 2015-12-11 2020-04-23 Treatment of cancer with dual targeting of CD47 and EGFR
AU2023201938A Active AU2023201938B2 (en) 2015-12-11 2023-03-30 Treatment of cancer with dual targeting of CD47 and EGFR

Country Status (8)

Country Link
US (3) US10344094B2 (enExample)
EP (1) EP3386545A4 (enExample)
JP (2) JP7077226B2 (enExample)
KR (2) KR20250004896A (enExample)
CN (2) CN108367073A (enExample)
AU (3) AU2016365829B2 (enExample)
CA (1) CA3005911A1 (enExample)
WO (1) WO2017100462A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568383B2 (en) * 2015-01-16 2020-02-25 Nike, Inc. Sole system for an article of footwear incorporating a knitted component with a one-piece knit outsole and a tensile element
US9848673B2 (en) 2015-01-16 2017-12-26 Nike, Inc. Vacuum formed knit sole system for an article of footwear incorporating a knitted component
JP7198083B2 (ja) * 2015-08-26 2022-12-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７遮断及び免疫同時刺激アゴニストを用いた標的細胞の枯渇亢進
CN108367073A (zh) * 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
EA038880B1 (ru) 2016-01-11 2021-11-01 Форти Севен, Инк. Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
US10995152B2 (en) 2016-10-26 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
KR102776457B1 (ko) * 2017-10-18 2025-03-06 포티 세븐, 엘엘씨 항-cd47 작용제-기초된 난소암 요법
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
ES2927305T3 (es) 2018-02-12 2022-11-04 Forty Seven Inc Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20
US20210040219A1 (en) * 2018-03-13 2021-02-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by egfr antibody
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
CN110331200A (zh) * 2019-06-28 2019-10-15 中山大学附属第六医院 Cd47检测试剂在制备结直肠癌对抗egfr单抗耐药诊断剂方面的应用
WO2021046216A1 (en) * 2019-09-03 2021-03-11 Arch Oncology, Inc. Methods for identifying biomarkers to predict treatment response
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
WO2023165618A1 (en) * 2022-03-04 2023-09-07 Nanjing University Methods for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131453A1 (en) * 2008-04-23 2009-10-29 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system.
WO2012058592A2 (en) * 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20130236449A1 (en) * 2010-04-21 2013-09-12 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
HRP20170254T1 (hr) 2010-05-14 2017-04-21 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
US20140134158A1 (en) 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
JP6426693B2 (ja) 2013-03-15 2018-11-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ｃｄ４７薬の処理上有効量を達成するための方法
KR20150130349A (ko) * 2013-03-15 2015-11-23 메르크 파텐트 게엠베하 4가 이중특이적 항체
WO2014179132A1 (en) * 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
JP6606505B2 (ja) * 2014-03-11 2019-11-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
US20160036232A1 (en) 2015-10-09 2016-02-04 LT Lighting (Taiwan) Corp. Maximum energy utilization point tracking technologies
CN108367073A (zh) 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
CN107459579B (zh) * 2016-06-01 2021-09-24 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
CN106519036B (zh) * 2016-11-04 2019-06-11 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131453A1 (en) * 2008-04-23 2009-10-29 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system.
WO2012058592A2 (en) * 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEISKOPF, K., et al., "Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies", Science, July 2013, Volume 341, Number 6141, Pages 88-91 *

Also Published As

Publication number Publication date
AU2023201938A1 (en) 2023-05-04
US20190322751A1 (en) 2019-10-24
US11130813B2 (en) 2021-09-28
CA3005911A1 (en) 2017-06-15
AU2023201938B2 (en) 2025-11-20
KR20180083895A (ko) 2018-07-23
US20170166645A1 (en) 2017-06-15
JP7077226B2 (ja) 2022-05-30
KR102763202B1 (ko) 2025-02-07
CN108367073A (zh) 2018-08-03
CN115569192A (zh) 2023-01-06
JP7494245B2 (ja) 2024-06-03
AU2016365829A1 (en) 2018-06-07
KR20250004896A (ko) 2025-01-08
AU2020202712B2 (en) 2023-01-05
US20220033506A1 (en) 2022-02-03
EP3386545A2 (en) 2018-10-17
JP2022116095A (ja) 2022-08-09
JP2019505485A (ja) 2019-02-28
US12037402B2 (en) 2024-07-16
AU2020202712A1 (en) 2020-05-14
US10344094B2 (en) 2019-07-09
WO2017100462A2 (en) 2017-06-15
EP3386545A4 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
US12037402B2 (en) Treatment of cancer with dual targeting of CD47 and EGFR
KR102418979B1 (ko) Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
JP7343528B2 (ja) 抗ｃｄ４７抗体及び抗ｃｄ２０抗体を使用する抗がんレジメン
JP2023085370A (ja) 免疫調節剤を併用するがんの治療
KR102644408B1 (ko) 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
EP3697819B1 (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
US20240425604A1 (en) Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
JP2025517656A (ja) 腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
HK40084229A (en) Treatment of cancer with dual targeting of cd47 and egfr
HK1259512A1 (en) Treatment of cancer with dual targeting of cd47 and egfr
TW202432605A (zh) 使用至少結合ｅｇｆｒ的抗體和免疫檢查點抑制劑組合治療癌症
HK40036031A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031B (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
EA045764B1 (ru) Иммунотерапия злокачественных опухолей путем нарушения передачи сигналов pd-1/pd-l1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)